Radotinib induces high cytotoxicity in c-KIT positive acute myeloid leukemia cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Heo, Sook-Kyoung | - |
dc.contributor.author | Noh, Eui-Kyu | - |
dc.contributor.author | Kim, Jeong Yi | - |
dc.contributor.author | Jo, Jae-Cheol | - |
dc.contributor.author | Choi, Yunsuk | - |
dc.contributor.author | Koh, Sujin | - |
dc.contributor.author | Baek, Jin Ho | - |
dc.contributor.author | Min, Young Joo | - |
dc.contributor.author | Kim, Hawk | - |
dc.date.available | 2020-02-27T18:41:52Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2017-06-05 | - |
dc.identifier.issn | 0014-2999 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/6004 | - |
dc.description.abstract | Previously, we reported that radotinib, a BCR-ABL1 tyrosine kinase inhibitor, induced cytotoxicity in acute myeloid leukemia (AML) cells. However, the effects of radotinib in the subpopulation of c-KIT-positive AML cells were unclear. We observed that low-concentration radotinib had more potent cytotoxicity in c-KIT-positive cells than c-KIT-negative cells from AML patients. To address this issue, cell lines with high c-KIT expression, HEL92.1.7, and moderate c-KIT expression, H209, were selected. HEL92.1.7 cells were grouped into intermediate and high c-HIT expression populations. The cytotoxicity of radotinib against the HEL92.1.7 cell population with intermediate c-HIT expression was not different from that of the population with high c-KIT expression. When H209 cells were grouped into c-KIT expression-negative and c-HIT expression-positive populations, radotinib induced cytotoxicity in the c-KIT-positive population, but not the c-KIT-negative population. Thus, radotinib induces cytotoxicity in c-KIT-positive cells, regardless of the c-KIT expression intensity. Therefore, radotinib induces significant cytotoxicity in c-KIT-positive AML cells, suggesting that radotinib is a potential target agent for the treatment of c-KIT-positive malignancies including AML. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF PHARMACOLOGY | - |
dc.subject | GASTROINTESTINAL STROMAL TUMORS | - |
dc.subject | METASTATIC MELANOMA | - |
dc.subject | IMATINIB MESYLATE | - |
dc.subject | KINASE-ACTIVITY | - |
dc.subject | PHASE-II | - |
dc.subject | CANCER | - |
dc.subject | ACTIVATION | - |
dc.subject | PROLIFERATION | - |
dc.subject | MALIGNANCIES | - |
dc.subject | INHIBITION | - |
dc.title | Radotinib induces high cytotoxicity in c-KIT positive acute myeloid leukemia cells | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000401200900008 | - |
dc.identifier.doi | 10.1016/j.ejphar.2017.03.040 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF PHARMACOLOGY, v.804, pp.52 - 56 | - |
dc.identifier.scopusid | 2-s2.0-85015745973 | - |
dc.citation.endPage | 56 | - |
dc.citation.startPage | 52 | - |
dc.citation.title | EUROPEAN JOURNAL OF PHARMACOLOGY | - |
dc.citation.volume | 804 | - |
dc.contributor.affiliatedAuthor | Kim, Hawk | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Radotinib | - |
dc.subject.keywordAuthor | Acute myeloid leukemia | - |
dc.subject.keywordAuthor | c-KIT | - |
dc.subject.keywordAuthor | CD117 | - |
dc.subject.keywordAuthor | Cytotoxicity | - |
dc.subject.keywordAuthor | Anti-leukemic activity | - |
dc.subject.keywordPlus | GASTROINTESTINAL STROMAL TUMORS | - |
dc.subject.keywordPlus | METASTATIC MELANOMA | - |
dc.subject.keywordPlus | IMATINIB MESYLATE | - |
dc.subject.keywordPlus | KINASE-ACTIVITY | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | PROLIFERATION | - |
dc.subject.keywordPlus | MALIGNANCIES | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.